Synthesis and in vivo antihyperglycemic activity of 5-(1H-pyrazol-3-yl)methyl-1H-tetrazoles
- 15 April 2005
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 15 (8), 2115-2117
- https://doi.org/10.1016/j.bmcl.2005.02.060
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010Diabetic Medicine, 1997
- Non‐insulin dependent diabetes mellitus: defects in insulin secretionEuropean Journal of Clinical Investigation, 1993
- Diabetes, Exercise, and AtherosclerosisDiabetes Care, 1992
- Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up studyThe Lancet, 1992
- Pathogenesis of NIDDM: A Balanced OverviewDiabetes Care, 1992
- Oral Hypoglycemic AgentsThe New England Journal of Medicine, 1989
- Perfluoro-N-[4-(1H-tetrazol-5-ylmethyl)phenyl]alkanamides. A new class of oral antidiabetic agentsJournal of Medicinal Chemistry, 1989
- Studies on antidiabetic agents. VI. Asymmetric transformation of (.+-.)-5-(4-(1-methylcyclohexylmethoxy)benzyl)-2,4-thiazolidinedione(ciglitazone) with optically active 1-phenylethylamines.CHEMICAL & PHARMACEUTICAL BULLETIN, 1984
- Therapeutic approaches to reducing insulin resistance in patients with noninsulin-dependent diabetes mellitusAmerican Journal Of Medicine, 1983
- Studies on antidiabetic agents. II. Synthesis of 5-(4-(1-methylcyclohexylmethoxy)-benzyl)thiazolidine-2,4-dione (ADD-3878) and its derivatives.CHEMICAL & PHARMACEUTICAL BULLETIN, 1982